Jonathan McKinnon, MD
Neurology · Las Vegas, NVNPI 1730159385
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $4,620 of the $6,986 with a category attached, or 66.1%. AstraZeneca accounts for 76.5% of it on its own, with 21 other manufacturers making up the rest. Reporting peaked in 2020 at $5,426 and has fallen 96.2% since, to $207 in 2025.
Across 69 payments — averaging $101.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$5K
- Biogen$586
- Tanabe Pharma America, Inc.$176
- Catalyst Pharmaceuticals, Inc.$98
- PTC Therapeutics, Inc.$96
- Sarepta Therapeutics, Inc.$84
- plus $599 from 16 others
Across 81 payments — averaging $6605.31 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$236K
- Sarepta Therapeutics, Inc.$158K
- Roche Products Limited$79K
- UCB SA$20K
- Tanabe Pharma America, Inc.$19K
- Hoffmann-la Roche Limited$16K
- plus $7K from 2 others
What the payments were for
- Consulting fees$4,62066%
- Travel & lodging$5938%
- Food & beverage$1,39920%
- Education$3735%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 7 | $5,346 |
| Biogen | 11 | $586 |
| Tanabe Pharma America, Inc. | 8 | $176 |
| Catalyst Pharmaceuticals, Inc. | 4 | $98 |
| PTC Therapeutics, Inc. | 5 | $96 |
| Sarepta Therapeutics, Inc. | 4 | $84 |
| AbbVie | 4 | $77 |
| Novartis Gene Therapies, Inc. (fka Avexis, Inc.) | 4 | $70 |
| Bristol Myers Squibb | 3 | $60 |
| Ipsen Biopharmaceuticals, Inc | 2 | $55 |
| Grifols USA, LLC | 2 | $45 |
| Pfizer | 1 | $38 |
| Sunovion Pharmaceuticals Inc. | 4 | $37 |
| Johnson & Johnson | 1 | $34 |
| Genentech USA, Inc. | 2 | $31 |
| Amicus Therapeutics, Inc. | 1 | $27 |
| UCB, Inc. | 1 | $26 |
| Amylyx Pharmaceuticals, Inc. | 1 | $25 |
| Kyowa Kirin, Inc. | 1 | $21 |
| GSK | 1 | $20 |
| Sobi, Inc | 1 | $17 |
| CSL Behring | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SPINRAZA$125
How this compares
$6,986 in reported general payments places this provider in the 65th percentile of 145 neurology providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| SolirisEculizumab | 40 | $1,886,786 |
| NexviazymeAvalglucosidase Alfa-Ngpt | 13 | $1,091,341 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 80 | $969,454 |
| GammaplexImmun Glob G(Igg)/Gly/Iga 0-50 | 64 | $893,850 |
| PrivigenImmun Glob G(Igg)/Pro/Iga 0-50 | 62 | $703,025 |
| Radicava OrsEdaravone | 45 | $607,453 |
| GammakedImmune Globul G/Gly/Iga Avg 46 | 15 | $353,407 |
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 25 | $262,722 |
| VimpatLacosamide | 12 | $13,821 |
| Riluzole | 31 | $13,591 |
| Azathioprine | 14 | $7,306 |
| Pyridostigmine Bromide | 44 | $4,589 |
| Gabapentin | 91 | $1,820 |
| Mycophenolate Mofetil | 38 | $1,646 |
| Levetiracetam | 64 | $1,594 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaSoliris | $5,346 | $1,886,78640 claims |
| Grifols USA, LLCGamunex-C | $45 | $969,45480 claims |
| CSL BehringPrivigen | $16 | $703,02562 claims |
| UCB, Inc.Vimpat | $26 | $13,82112 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 145 neurology providers in Nevada.
Other neurology in Las Vegas
- Zoltan MariLas Vegas$629K
- Fan ZhangLas Vegas$398K
- le HuaLas Vegas$385K
- Mehdi AnsariniaLas Vegas$306K
- Carrie HershLas Vegas$209K
- Shanker DixitLas Vegas$137K
- Charles KamenLas Vegas$124K
- Toya MaloneLas Vegas$123K
- Nicole TheuvenetLas Vegas$120K
- Kevin XieLas Vegas$46K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.